| Abstract: |
Prostate cancer remains the most common form of noncutaneous malignancy and the second leading cause of cancer death in American men. It is estimated that more than 198,000 men will be diagnosed with prostate cancer in the United States, and 31,500 will die of this disease [1]. Because prostate cancer incidence increases rapidly with age, the absolute number of diagnosed cases is destined to rise worldwide as life expectancy increases. Indeed, the number of men older than 65 years is likely to double from 1990 to 2020. Prostate cancer will not only cause the death of 3% of all men alive today who are over 50 years old, but will also cause many men to suffer serious complications from local tumor growth or distant metastases, as well as from complications of treatment. © 2004 by Taylor & Francis Group, LLC. |
